上海科技大学知识管理系统

Thyroid hormone receptors (THRs), a crucial nuclear receptor protein family, primarily consist of two categories: a receptors and /3 receptors. Among them, THR/3 is the primary subtype of thyroid hormone that confers benefits to the liver. In the last two decades, there have been efforts to develop THR/3 agonists that selectively yield beneficial effects on the liver, such as lowering triglycerides and cholesterol, while reducing adverse effects on the heart, muscle, and bone. This paper systematically reviews strategies to enhance the safety of THR/3 agonists for the treatment of MASH, with a focus on improving the selectivity of THRa and increasing the distribution of the drug in the liver. Additionally, we explore the potential application of this target in addressing other medical indications. (c) 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).